ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2019

SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions.

Naser Eddin Gharaibeh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.